Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07037420 · ClinicalTrials.gov registry record · Phase 2

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

A Phase 2 study of Acromegaly, sponsored by Alexion Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
20
Study locations

NCT07037420 is a Phase 2 study of Acromegaly that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 60 participants, below the 96-participant average among 13 other Acromegaly trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07037420, a Phase 2 study of Acromegaly, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog (SSA) therapy to adult participants with acromegaly.

Conditions Studied

Acromegaly

Interventions

  • DRUG Placebo
  • DRUG ALXN2420

Study Locations (20)

Other

  • Research Site - CABA
  • Research Site - Ciudad de Buenos Aires
  • Research Site - Ciudad de Buenos Aires
  • Research Site - Ciudad de Buenos Aires
  • Research Site - Curitiba
  • Research Site - Ribeirão Preto
  • Research Site - Rio de Janeiro
  • Research Site - São Paulo
  • Research Site - Beijing
  • Research Site - Guangzhou
  • Research Site - Kunming

California

  • Research Site - Los Angeles
  • Research Site - Los Angeles
  • Research Site - Torrance

Colorado

  • Research Site - Aurora

Massachusetts

  • Research Site - Boston

Michigan

  • Research Site - Ann Arbor

Nevada

  • Research Site - Las Vegas

New York

  • Research Site - New York

Oregon

  • Research Site - Portland

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-10-28
Est. Completion 2027-11-11
Phase Phase 2

Sponsor

Alexion Pharmaceuticals

162 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07037420

The ClinicalTrials.gov registry entry for NCT07037420 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 13 other Acromegaly trials with a reported enrollment target (37% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acromegaly appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07037420 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT07037420 about?

NCT07037420 is a clinical study titled "ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly". The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog (SSA) therapy to adult participants with acromegaly.

What is the current status of trial NCT07037420?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-10-28. Estimated completion is 2027-11-11.

What conditions does trial NCT07037420 study?

This clinical trial studies the following conditions: Acromegaly.

What interventions are being tested in trial NCT07037420?

The interventions under investigation include: Placebo (DRUG), ALXN2420 (DRUG).

Who is sponsoring clinical trial NCT07037420?

This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07037420 being conducted?

This trial has 20 study locations across California, Colorado, Massachusetts, Michigan, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acromegaly

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acromegaly

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.